Hikma Pharmaceuticals
HIK.LDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
praziquantel | Phase 3 | Schistosomiasis | - | - |
Dasatinib | Phase 2 | Chronic Myelogenous Leukemia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Hikma Pharmaceuticals's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Hikma Pharmaceuticals's (HIK.L) pipeline across Phase 3, Phase 2. Its lead program is praziquantel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hikma Pharmaceuticals's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Hikma Pharmaceuticals (HIK.L) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HIK.L biotech catalysts?→
Add HIK.L to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hikma Pharmaceuticals's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.